Ivabradine hemisulfate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 576817

CAS#: 1422274-66-5 (hemisulfate)

Description: Ivabradine hemisulfate is a novel biochemical for symptomatic management of stable angina pectoris.

Chemical Structure

img
Ivabradine hemisulfate
CAS# 1422274-66-5 (hemisulfate)
Instruction

Theoretical Analysis

MedKoo Cat#: 576817
Name: Ivabradine hemisulfate
CAS#: 1422274-66-5 (hemisulfate)
Chemical Formula: C54H74N4O14S
Exact Mass: 1,034.49
Molecular Weight: 1,035.260
Elemental Analysis: C, 62.65; H, 7.21; N, 5.41; O, 21.64; S, 3.10

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 155974-00-8 (free base)   1202000-62-1 (sulfate)   148849-67-6 (HCl)   1086026-42-7 (oxalate)   1422274-66-5 (hemisulfate)  

Synonym: Ivabradine hemisulfate

IUPAC/Chemical Name: 2H-3-Benzazepin-2-one, 3-(3-((((7S)-3,4-dimethoxybicyclo(4.2.0)octa-1,3,5-trien-7-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-, sulfate (2:1)

InChi Key: AMRKLKWJQKOGOF-ITEXDBGESA-N

InChi Code: InChI=1S/2C27H36N2O5.H2O4S/c2*1-28(17-21-11-20-14-25(33-4)26(34-5)16-22(20)21)8-6-9-29-10-7-18-12-23(31-2)24(32-3)13-19(18)15-27(29)30;1-5(2,3)4/h2*12-14,16,21H,6-11,15,17H2,1-5H3;(H2,1,2,3,4)/t2*21-;/m11./s1

SMILES Code: COc1cc2CCN(CCCN(C)C[C@H]3Cc4cc(OC)c(OC)cc34)C(=O)Cc2cc1OC.COc5cc6CCN(CCCN(C)C[C@H]7Cc8cc(OC)c(OC)cc78)C(=O)Cc6cc5OC.OS(=O)(=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 1,035.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548107/ PubMed PMID: 31643437.

2: Zhu H, Xu X, Fang X, Zheng J, Zhao Q, Chen T, Huang J. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials. Clin Ther. 2019 Oct;41(10):2137-2152.e12. doi: 10.1016/j.clinthera.2019.08.008. Epub 2019 Sep 21. Review. PubMed PMID: 31548105.

3: Mayhew A, Loshak H. Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 May 15. Available from http://www.ncbi.nlm.nih.gov/books/NBK545894/ PubMed PMID: 31487130.

4: Zhou Y, Wang J, Meng Z, Zhou S, Peng J, Chen S, Wang Q, Sun K. Pharmacology of Ivabradine and the Effect on Chronic Heart Failure. Curr Top Med Chem. 2019;19(21):1878-1901. doi: 10.2174/1568026619666190809093144. Review. PubMed PMID: 31400267.

5: Sattar Y, Neisani Samani E, Zafrullah F, Latchana S, Patel NB. Ivabradine in Congestive Heart Failure: Patient Selection and Perspectives. Cureus. 2019 Apr 13;11(4):e4448. doi: 10.7759/cureus.4448. Review. PubMed PMID: 31205834; PubMed Central PMCID: PMC6561528.

6: Katsi V, Skalis G, Kallistratos MS, Tsioufis K, Makris T, Manolis AJ, Tousoulis D. Ivabradine and metoprolol in fixed dose combination: When, why and how to use it. Pharmacol Res. 2019 Aug;146:104279. doi: 10.1016/j.phrs.2019.104279. Epub 2019 May 17. Review. PubMed PMID: 31108185.

7: Bocchi EA, Salemi VMC. Ivabradine for treatment of heart failure. Expert Opin Drug Saf. 2019 May;18(5):393-402. doi: 10.1080/14740338.2019.1612873. Epub 2019 May 10. Review. PubMed PMID: 31074301.

8: Sathyamurthy I, Newale S. Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications. Indian Heart J. 2018 Dec;70 Suppl 3:S435-S441. doi: 10.1016/j.ihj.2018.08.008. Epub 2018 Aug 20. Review. PubMed PMID: 30595304; PubMed Central PMCID: PMC6309574.

9: CADTH Canadian Drug Expert Committee Recommendation: Ivabradine Hydrochloride (Lancora — Servier Canada Inc.): Indication: Heart Failure, NYHA class II to III [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May 24. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK533855/ PubMed PMID: 30462447.

10: Pharmacoeconomic Review Report: Ivabradine hydrochloride (Lancora) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK533848/ PubMed PMID: 30462445.

11: Patient Group Input Submissions: Ivabradine (Lancora) for Heart failure, NYHA class II to IV [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK533856/ PubMed PMID: 30462443.

12: Clinical Review Report: Ivabradine hydrochloride (Lancora) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK533838/ PubMed PMID: 30462437.

13: Badu-Boateng C, Jennings R, Hammersley D. The therapeutic role of ivabradine in heart failure. Ther Adv Chronic Dis. 2018 Jul 4;9(11):199-207. doi: 10.1177/2040622318784556. eCollection 2018 Nov. Review. PubMed PMID: 30364460; PubMed Central PMCID: PMC6196638.

14: Dodd K, Lampert BC. The Use and Indication of Ivabradine in Heart Failure. Heart Fail Clin. 2018 Oct;14(4):493-500. doi: 10.1016/j.hfc.2018.06.001. Epub 2018 Aug 18. Review. PubMed PMID: 30266358.

15: Reed M, Nicolas D. Ivabradine. 2019 Oct 8. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK507783/ PubMed PMID: 29939560.

16: Chow SL, Page RL 2nd, Depre C. Role of ivabradine and heart rate lowering in chronic heart failure: guideline update. Expert Rev Cardiovasc Ther. 2018 Jul;16(7):515-526. doi: 10.1080/14779072.2018.1489235. Epub 2018 Jul 2. Review. PubMed PMID: 29902387.

17: Kaski JC, Gloekler S, Ferrari R, Fox K, Lévy BI, Komajda M, Vardas P, Camici PG. Role of ivabradine in management of stable angina in patients with different clinical profiles. Open Heart. 2018 Mar 9;5(1):e000725. doi: 10.1136/openhrt-2017-000725. eCollection 2018. Review. PubMed PMID: 29632676; PubMed Central PMCID: PMC5888443.

18: Gee ME, Watkins AK, Brown JN, Young EJA. Ivabradine for the Treatment of Postural Orthostatic Tachycardia Syndrome: A Systematic Review. Am J Cardiovasc Drugs. 2018 Jun;18(3):195-204. doi: 10.1007/s40256-017-0252-1. Review. PubMed PMID: 29330767.

19: Mathew ST, Po SS, Thadani U. Inappropriate sinus tachycardia-symptom and heart rate reduction with ivabradine: A pooled analysis of prospective studies. Heart Rhythm. 2018 Feb;15(2):240-247. doi: 10.1016/j.hrthm.2017.10.004. Epub 2017 Oct 7. Review. PubMed PMID: 29017929.

20: Kang S, Li CJ, Zhang XM. Ivabradine has a neutral effect on mortality in randomized controlled trials. Medicine (Baltimore). 2017 Oct;96(40):e8067. doi: 10.1097/MD.0000000000008067. Review. PubMed PMID: 28984762; PubMed Central PMCID: PMC5737998.